The FDA has given priority review to lecanemab, the second Alzheimer's disease drug made by Biogen and Japanese pharmaceutical firm Eisai, under the accelerated approval pathway — the same regulatory route used by the companies for Aduhelm.
The FDA has given priority review to lecanemab, the second Alzheimer's disease drug made by Biogen and Japanese pharmaceutical firm Eisai, under the accelerated approval pathway — the same regulatory route used by the companies for Aduhelm.
